Search

Your search keyword '"Paloma Morales de Los Ríos Luna"' showing total 2 results
Start Over Author "Paloma Morales de Los Ríos Luna" Topic biologics
2 results on '"Paloma Morales de Los Ríos Luna"'

1. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

Author

Néboa Zozaya, Renata Villoro, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, José Manuel Carrascosa Carrillo, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio García-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de los Ríos Luna, Lluis Puig Sanz, Sandra Ros, and Álvaro Hildago-Vega

Subjects
Psoriasis, moderate-to-severe, biologics, unmet needs, discrete choice, Dermatology, RL1-803
Abstract

Psoriasis is a chronic, systemic inflammatory disease that affects the skin, with a high impact on patients’ quality of life. The aim of this study was to identify and determine the relative importance of unmet needs in the management of moderate-to-severe psoriasis in Spain, from a multi-stakeholder perspective. A mixed method-approach was used to collect information, design a questionnaire and a discrete-choice exercise, and elicit the unmet needs through a multidisciplinary committee composed of 12 experts. A total of 65 unmet needs were identified and categorized into 4 areas: clinical, patient-related, decision-making process, and social. Decision-making process unmet needs were perceived as the most pressing ones, followed by social, clinical and patient-related. Individually, the need to incorporate outcomes that are important to the patients and to have treatments that achieve total clearance with a rapid onset of action and long-term persistence were the most important unmet needs.

Published
2022
Full Text
View/download PDF

2. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

Author

Néboa Zozaya, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, José Manuel Carrascosa Carrillo, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio García-Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de Los Ríos Luna, Lluis Puig, Sandra Ros, and Álvaro HIdalgo-Vega

Subjects
Health Policy, Adalimumab, General Medicine, MCDA, multi-criteria decision analysis, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Decision Support Techniques, moderate-to-severe, Treatment Outcome, Humans, Psoriasis, Pharmacology (medical), biologics, bimekizumab
Abstract

Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and risankizumab. The EVIDEM framework was adapted to reflect relevant criteria for the assessment. Estimated values were obtained by means of an additive linear model combining weights and scores assigned by a multidisciplinary committee of 12 experts. Consistency and replicability were evaluated through an alternative weighting method and a re-test. Bimekizumab was assessed by the committee as an intervention with a positive value contribution for the treatment of moderate-to-severe psoriasis in comparison to any of the alternatives. The drug provides a substantial therapeutical benefits and improves the health results reported by the patients, as it combines a higher level of clearance, rapidity, and persistence with a similar safety and tolerability profile. Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results